Suchergebnisse

In 2011, federal spending for prescription drugs by DOD, Medicaid, and Medicare Part D totaled 71.2 billion-representing about 85 percent of all federal prescription drug expenditures-for about 114.4 million beneficiaries. Each program reimbursed retail pharmacies for outpatient prescriptions filled at these pharmacies by their beneficiaries. This book compares retail reimbursement prices paid by DOD, Medicaid, and Medicare Part D for a sample of prescription drugs and describes factors affecting these prices. It also discusses approaches to control prescription drug spending in federal progra

The Right Price provides an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

Testimony issued by the Government Accountability Office with an abstract that begins "Several federal programs help pay for or reduce the costs of prescription drugs for eligible individuals and entities. Three examples are the Medicaid drug rebate program, part of the joint federal-state Medicaid program that finances medical services for certain low-income people; the 340B drug pricing program, which provides discounted drug prices to certain eligible entities such as community health centers; and the Medicare Part D program, which provides a Medicare drug benefit for the elderly and certain disabled people. The price information drug manufacturers report under these federal programs affects related federal spending. Spending is also affected by the extent to which federal oversight ensures the accuracy of this information. GAO was asked to provide information related to the oversight of prescription drug pricing practices that affect these federal programs. This testimony focuses on the oversight of drug pricing related to the three programs and the implications for future congressional oversight. This testimony is based on recent GAO reports examining these programs and related work by the Department of Health and Human Services Office of Inspector General and others."

Shipping list no.: 95-0258-P. ; Distributed to some depository libraries in microfiche. ; Includes bibliographical references. ; Mode of access: Internet.

"Serial no. 108-63." ; Distributed to some depository libraries in microfiche. ; Shipping list no.: 2004-0046-P. ; Mode of access: Internet.

"July 27, 1994." ; Cover title. ; Includes bibliographical references. ; Mode of access: Internet.